Immunic Therapeutics

Developing Selective Oral Drugs in Immunology

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis.


Immunic, Inc. is headquartered in New York. Its subsidiary, Immunic AG, is based in Gräfelfing near Munich, Germany, where the company’s research and development activities are conducted. Additional subsidiaries are located in Halle (Saale), Germany, and Melbourne, Australia.

Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic announced positive results from its phase 2 EMPhASIS trial of IMU-838 in patients with relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn’s disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic.

Development of Innovative COVID-19 Therapies Needs Additional Public Funding to Help Patients in the Short-Term (in German Only)

Entwicklung innovativer COVID-19-Medikamente bedarf weitergehender öffentlicher Förderung, um Patienten schnell zu helfen Deutschland, 08. Januar 2021 – Die Initiative BEAT-COV (Biotech Emergency Alliance for Therapies against COVID-19) begrüßt die Antwort ...
Read More

Immunic, Inc. to Participate in Investor Conferences in January

– Management Provides Update on Timing of Data for IMU-838 in Primary Sclerosing Cholangitis – NEW YORK, January 5, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing ...
Read More

Immunic, Inc. Added to NASDAQ Biotechnology Index

NEW YORK, December 14, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced ...
Read More